Audentes Therapeutics (BOLD) Set to Announce Earnings on Tuesday

Audentes Therapeutics (NASDAQ:BOLD) will release its earnings data after the market closes on Tuesday, August 6th. Analysts expect Audentes Therapeutics to post earnings of ($1.08) per share for the quarter.

Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.23). During the same quarter in the previous year, the firm posted ($0.74) EPS. On average, analysts expect Audentes Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

NASDAQ:BOLD traded down $0.15 during midday trading on Wednesday, reaching $39.96. The stock had a trading volume of 4,194 shares, compared to its average volume of 332,569. The business’s fifty day simple moving average is $37.87. Audentes Therapeutics has a 12-month low of $17.95 and a 12-month high of $41.65. The stock has a market cap of $1.77 billion, a PE ratio of -11.78 and a beta of 1.71.

A number of equities research analysts have commented on the company. Wedbush reissued a “hold” rating and issued a $2.00 target price on shares of Regulus Therapeutics in a report on Tuesday, April 9th. Svb Leerink boosted their target price on shares of Audentes Therapeutics from $37.00 to $48.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. ValuEngine raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday. Zacks Investment Research downgraded shares of ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday, July 10th. Finally, HC Wainwright set a $31.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a research note on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating, twelve have given a buy rating and two have given a strong buy rating to the company. Audentes Therapeutics currently has an average rating of “Buy” and an average price target of $39.99.

In other Audentes Therapeutics news, Director Louis G. Lange sold 21,000 shares of Audentes Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $37.79, for a total value of $793,590.00. Following the completion of the sale, the director now owns 290,001 shares in the company, valued at approximately $10,959,137.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Suyash Prasad sold 10,000 shares of Audentes Therapeutics stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $36.98, for a total value of $369,800.00. Following the completion of the sale, the vice president now owns 28,236 shares of the company’s stock, valued at approximately $1,044,167.28. The disclosure for this sale can be found here. 5.30% of the stock is owned by insiders.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

See Also: Hedge Funds

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.